Supernus Inc. (SUPN)
SUPN trades on Nasdaq in Health Care, Biotechnology: Pharmaceutical Preparations. Numbers below come from the Nasdaq screener and SEC filings, each with its source.
Price, change, market cap, sector and industry: Nasdaq stock screener, as of November 16, 2026. Revenue: SEC 10-K (us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax), fiscal year ended 2025-12-31, https://www.sec.gov/Archives/edgar/data/1625297/000162828026012237/0001628280-26-012237-index.htm. Net income: SEC 10-K (us-gaap:NetIncomeLoss), fiscal year ended 2025-12-31.
Profile
| Field | Value |
|---|---|
| Ticker | SUPN on Nasdaq |
| Sector | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations |
| Country | United Kingdom |
| IPO year | Not reported by the screener |
| SEC CIK | 0001625297 |
| SEC industry code | Pharmaceutical Preparations |
| Incorporated in | DE |
Financials · 2025
| Line | Value |
|---|---|
| Revenue | $1.2B |
| Net income | $210.0M |
| Operating income | $262.0M |
| Net margin | 16.9% |
| Operating margin | 21.1% |
| Revenue growth | +4.3% |
| Cash | $195.0M |
| Total assets | $1.2B |
| P/E (computed) | 28.5× |
| P/S (computed) | 4.8× |
Warning signs
| Sign | Finding | Source |
|---|---|---|
| Going concern | No going-concern finding. | 10-Q 2026-10-29 |
| Cash and burn | $305.0M cash; operating cash flow $24.0M a quarter. | Report 2026-09-30 |
| Shares outstanding | 118,035,272 (2026-10-09); 124,853,897 a year earlier; 136,526,357 three years earlier. | Cover page 2026-10-09 |
| Reverse splits, 3 years | None found | None on EDGAR |
| Shelf and offerings, 12 months | 0 S-3/F-3 shelf filings; 0 424B5 takedowns | None on EDGAR |
| Exchange deficiency notices, 12 months | None | None on EDGAR |
| Auditor | PricewaterhouseCoopers LLP, Richmond, Virginia, United States | PCAOB Form AP 2026-03-18 |
| Late filings, 12 months | None | None on EDGAR |
| Insider trades, 12 months | Bought $229K, sold $2.8M on the open market | SEC Forms 3/4/5 data sets 2026-09-30 |
| Market cap check | The listing's market cap implies 207,724,098 shares at the 2026-11-13 price; the latest SEC cover count is 118,035,272 as of 2026-10-09. One of the two share counts is stale. | Nasdaq screener and SEC cover page |
From SEC EDGAR submissions, EDGAR full-text search, SEC's Forms 3/4/5 data sets and PCAOB Form AP; computed November 16, 2026. Runway is cash divided by average quarterly operating cash burn. Dilution compares cover-page share counts, corrected for recorded splits.
Quarterly results
| Quarter | Revenue | Net income | Op. cash flow | Cash | Total debt | TTM revenue | Source |
|---|---|---|---|---|---|---|---|
| Q3 2026 2026-09-30 | $356.0M | $137.0M | $97.0M | $305.0M | $488.0M | $1.4B | 10-Q 2026-10-29 |
| Q2 2026 2026-06-30 | $343.0M | $122.0M | $229.0M | $222.0M | $487.0M | $1.3B | 10-Q 2026-08-03 |
| Q1 2026 2026-03-31 | $317.0M | $89.0M | -$9.0M | $175.0M | $486.0M | $1.3B | 10-Q 2026-04-30 |
| Q4 2025 2025-12-31 | $358.0M | $102.0M | -$221.0M | $195.0M | $319.0M | $1.2B | 10-K 2026-02-26 |
| Q3 2025 2025-09-30 | $314.0M | $42.0M | -$39.0M | $445.0M | $322.0M | $1.2B | 10-Q 2026-10-29 |
| Q2 2025 2025-06-30 | $302.0M | $18.0M | $158.0M | $510.0M | $326.0M | $1.2B | 10-Q 2026-08-03 |
| Q1 2025 2025-03-31 | $266.0M | $47.0M | $75.0M | $372.0M | $329.0M | $1.2B | 10-Q 2026-04-30 |
| Q4 2024 2024-12-31 | $299.0M | $21.0M | -$17.0M | $319.0M | $333.0M | $1.2B | 10-K 2026-02-26 |
From SEC XBRL company facts. Quarters a filing gives only as year-to-date are computed as differences (Q4 is the fiscal year minus nine months).
Key SEC documents
| Document | Form | Filed |
|---|---|---|
| Latest prospectus or offering document | 424B3 | 2026-09-11 |
| Latest annual report | 10-K | 2026-02-26 |
| Latest quarterly / interim | 10-Q | 2026-10-29 |
| Latest current report | 8-K | 2026-11-03 |
| Latest proxy | DEFA14A | 2026-03-27 |
Source: SEC EDGAR submissions feed, 572 recent filings. All filings on EDGAR.
Price moves
| Window | Return |
|---|---|
| 1 week | +13.6% |
| 1 month | -16.1% |
| 3 months | -22.2% |
| Year to date | -17.2% |
| 1 year | -0.4% |
| From 52-week high | -29.0% |
Source: Yahoo Finance daily closes, last bar 2026-11-13. Computed by MarginsX from daily closes; cap, sector and tier from the Nasdaq screener.
Peers in Biotechnology: Pharmaceutical Preparations
| Ticker | Company | Price | Day | Market cap |
|---|---|---|---|---|
| MIRM | Mirum Pharmaceuticals Inc. | $91.58 | -2.56% | $6.0B |
| GRFS | Grifols S.A. | $8.73 | +0.46% | $6.0B |
| LGND | Ligand Pharmaceuticals Incorporated | $301.71 | -2.29% | $6.0B |
| ARWR | Arrowhead Pharmaceuticals Inc. | $44.21 | -7.47% | $6.2B |
| BLTE | Belite Bio Inc | $162.56 | -1.09% | $6.5B |
| MANE | Veradermics Incorporated | $128.05 | -1.24% | $5.4B |
| ERAS | Erasca Inc. | $15.11 | -3.51% | $5.3B |
| PTCT | PTC Therapeutics Inc. | $60.97 | -3.97% | $5.1B |
The full dossier has every filing, three years of financials, private raises and the people who signed them.
Open the full dossier